Abstract:Abstract To date, dysregulation of more than 450 RNA-binding proteins (RBPs) across a multitude of cancers has been implicated in tumorigenesis and chemoresistance. In fact, emerging evidence suggests RBPs are principal modulators of every hallmark of cancer progression. Functionally, RBPs are believed to modulate the stability, localization, and translation of transcripts encoding for virtually all known oncogenes and tumor suppressor genes. Consequently, aberrant expression of RBPs may contribute to the malignant transformation of cancer cells through enhancing the expression of oncogenes or decreasing the expression of tumors suppressor genes, such as TP53. As a potent transcription factor, TP53 is a leading regulator of numerous signaling pathways involved in tumor suppression. While mutation or deletion of TP53 contributes to tumorigenesis in more than half of all human cancers, suppression of wild-type TP53 expression also drives tumorigenesis. Thus far, multiple RBPs have been implicated in the repression of wild-type TP53, such as RNA-binding motif protein 38 (RBM38). Specifically, RBM38 interacts with eukaryotic translation initiation factor 4E (EIF4E) on the TP53 transcript, preventing EIF4E from binding to TP53 m7G cap, thus inhibiting TP53 translation. We previously demonstrated that Pep8, an 8 amino acid peptide derived from RBM38, disrupts the RBM38-EIF4E complex enhancing TP53 expression. Moreover, Pep8 alone or in combination with doxorubicin, significantly decreased tumor xenograft growth. As activation of wild-type TP53 by targeting non-genetic mechanisms that inhibit TP53 expression is a promising therapeutic tactic for malignancies that carry wild-type TP53, we are developing more efficacious Pep8 derivatives as a novel therapeutic approach for cancers that express wild-type TP53. Citation Format: Chris August Lucchesi, Jin Zhang, Xinbin Chen. Targeting the RBM38-EIF4E complex to increase wild-type p53 as a novel cancer therapeutic strategy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1037.

The isolation of an RNA aptamer targeting to p53 protein with single amino acid mutation

Abstract 1037: Targeting the RBM38-EIF4E Complex to Increase Wild-Type P53 As a Novel Cancer Therapeutic Strategy

An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer

RNA Interference Targeting Mutant P53 Inhibits Growth and Induces Apoptosis in DU145 Human Prostate Cancer Cells

RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule

High-Fidelity and Simultaneous Sensing of Endogenous Mutant and Wild p53 Proteins for Precise Cancer Diagnosis and Drug Screening

Antisense-mediated splicing correction as a therapeutic approach for p53 K120R mutation

In Silico Screening, Molecular Dynamics Simulation and Binding Free Energy Identify Single-Point Mutations That Destabilize p53 and Reduce Binding to DNA

Synthesis of RNA-based Gene Regulatory Devices for Redirecting Cellular Signaling Events Mediated by P53

Silencing of Mutant P53 by Sirna Induces Cell Cycle Arrest and Apoptosis in Human Bladder Cancer Cells

Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant

Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations

DNA-delivered monoclonal antibodies targeting the p53 R175H mutant epitope inhibit tumor development in mice

Surface enhanced Raman spectroscopy based immunosensor for ultrasensitive and selective detection of wild type p53 and mutant p53R175H

Promising Proteolysis-Targeting Chimera for Mutant p53-R175H

Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities

Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen

p53 protein abundance is a therapeutic window across TP53 mutant cancers and is targetable with proximity inducing small molecules

Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation

Targeting mutant p53 for efficient cancer therapy

Construction Of P53 Antisense Rna Expression Vector And Its Effect On Colon Cancer Cells